ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 247 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $208,995,709 | -13.1% | 10,028,585 | -0.1% | 0.01% | -14.3% |
| Q2 2023 | $240,446,049 | +29.5% | 10,039,501 | +1.7% | 0.01% | +40.0% |
| Q1 2023 | $185,737,046 | +13.7% | 9,869,131 | -3.8% | 0.01% | 0.0% |
| Q4 2022 | $163,326,211 | +0.1% | 10,259,184 | +2.9% | 0.01% | -16.7% |
| Q3 2022 | $163,161,000 | +18.9% | 9,973,155 | +2.4% | 0.01% | +50.0% |
| Q2 2022 | $137,256,000 | -43.2% | 9,741,314 | -2.3% | 0.00% | -42.9% |
| Q1 2022 | $241,472,000 | +2.8% | 9,970,023 | -0.9% | 0.01% | +16.7% |
| Q4 2021 | $234,810,000 | +39.2% | 10,060,312 | -0.9% | 0.01% | +20.0% |
| Q3 2021 | $168,673,000 | -31.8% | 10,154,951 | +0.2% | 0.01% | -28.6% |
| Q2 2021 | $247,295,000 | +29.5% | 10,139,203 | +37.0% | 0.01% | +16.7% |
| Q1 2021 | $190,960,000 | -50.6% | 7,401,602 | +2.4% | 0.01% | -50.0% |
| Q4 2020 | $386,560,000 | +30.9% | 7,230,797 | +1.0% | 0.01% | +9.1% |
| Q3 2020 | $295,400,000 | -21.4% | 7,161,211 | -7.7% | 0.01% | -26.7% |
| Q2 2020 | $376,022,000 | -12.2% | 7,757,846 | -23.5% | 0.02% | -28.6% |
| Q1 2020 | $428,249,000 | -2.2% | 10,136,110 | -1.0% | 0.02% | +23.5% |
| Q4 2019 | $438,020,000 | +27.7% | 10,238,895 | +7.4% | 0.02% | +21.4% |
| Q3 2019 | $342,960,000 | +32.9% | 9,529,325 | -1.3% | 0.01% | +27.3% |
| Q2 2019 | $258,040,000 | -10.3% | 9,653,564 | -9.9% | 0.01% | -15.4% |
| Q1 2019 | $287,799,000 | +75.6% | 10,718,708 | +5.8% | 0.01% | +62.5% |
| Q4 2018 | $163,859,000 | -19.4% | 10,133,466 | +3.5% | 0.01% | -11.1% |
| Q3 2018 | $203,175,000 | +36.7% | 9,786,905 | +0.5% | 0.01% | +28.6% |
| Q2 2018 | $148,654,000 | -0.5% | 9,735,101 | +46.4% | 0.01% | 0.0% |
| Q1 2018 | $149,407,000 | -26.1% | 6,649,227 | -0.9% | 0.01% | -30.0% |
| Q4 2017 | $202,060,000 | -16.0% | 6,710,697 | +5.0% | 0.01% | -16.7% |
| Q3 2017 | $240,664,000 | +54.3% | 6,388,747 | +14.3% | 0.01% | +50.0% |
| Q2 2017 | $155,925,000 | -16.5% | 5,590,706 | +2.9% | 0.01% | -20.0% |
| Q1 2017 | $186,791,000 | +6484.1% | 5,433,209 | +5422.8% | 0.01% | +150.0% |
| Q4 2016 | $2,837,000 | +562.9% | 98,377 | +630.3% | 0.00% | +300.0% |
| Q3 2016 | $428,000 | +6.7% | 13,471 | +8.8% | 0.00% | 0.0% |
| Q2 2016 | $401,000 | +163.8% | 12,377 | +128.6% | 0.00% | – |
| Q1 2016 | $152,000 | +87.7% | 5,414 | +139.5% | 0.00% | – |
| Q4 2015 | $81,000 | +42.1% | 2,261 | +31.5% | 0.00% | – |
| Q3 2015 | $57,000 | -33.7% | 1,719 | -16.4% | 0.00% | – |
| Q2 2015 | $86,000 | +26.5% | 2,056 | -1.1% | 0.00% | – |
| Q1 2015 | $68,000 | +3.0% | 2,078 | 0.0% | 0.00% | – |
| Q4 2014 | $66,000 | +10.0% | 2,078 | -13.7% | 0.00% | – |
| Q3 2014 | $60,000 | +9.1% | 2,408 | 0.0% | 0.00% | – |
| Q2 2014 | $55,000 | -9.8% | 2,408 | -4.1% | 0.00% | – |
| Q1 2014 | $61,000 | +3.4% | 2,511 | +6.2% | 0.00% | – |
| Q4 2013 | $59,000 | -9.2% | 2,364 | 0.0% | 0.00% | – |
| Q3 2013 | $65,000 | -91.7% | 2,364 | -94.5% | 0.00% | -100.0% |
| Q2 2013 | $784,000 | – | 43,241 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |